These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 21158978)

  • 21. Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice.
    Morgan D
    Neurochem Int; 2006 Jul; 49(2):190-4. PubMed ID: 16740342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease.
    Wilcock DM; Gharkholonarehe N; Van Nostrand WE; Davis J; Vitek MP; Colton CA
    J Neurosci; 2009 Jun; 29(25):7957-65. PubMed ID: 19553436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy.
    Bacskai BJ; Kajdasz ST; McLellan ME; Games D; Seubert P; Schenk D; Hyman BT
    J Neurosci; 2002 Sep; 22(18):7873-8. PubMed ID: 12223540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amyloid-beta immunotherapies in mice and men.
    Brendza RP; Holtzman DM
    Alzheimer Dis Assoc Disord; 2006; 20(2):118-23. PubMed ID: 16772748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccines for Alzheimer's disease: how close are we?
    Janus C
    CNS Drugs; 2003; 17(7):457-74. PubMed ID: 12751917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 'Clinical trials in Alzheimer's disease': immunotherapy approaches.
    Delrieu J; Ousset PJ; Caillaud C; Vellas B
    J Neurochem; 2012 Jan; 120 Suppl 1():186-193. PubMed ID: 21883222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities.
    Zago W; Schroeter S; Guido T; Khan K; Seubert P; Yednock T; Schenk D; Gregg KM; Games D; Bard F; Kinney GG
    Alzheimers Dement; 2013 Oct; 9(5 Suppl):S105-15. PubMed ID: 23583235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
    Panza F; Logroscino G; Imbimbo BP; Solfrizzi V
    Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunological approaches for amyloid-beta clearance toward treatment for Alzheimer's disease.
    Solomon B
    Rejuvenation Res; 2008 Apr; 11(2):349-57. PubMed ID: 18341423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Co-immunization with DNA and protein mixture: a safe and efficacious immunotherapeutic strategy for Alzheimer's disease in PDAPP mice.
    Liu S; Shi D; Wang HC; Yu YZ; Xu Q; Sun ZW
    Sci Rep; 2015 Jan; 5():7771. PubMed ID: 25586780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy for Alzheimer's disease.
    Gelinas DS; DaSilva K; Fenili D; St George-Hyslop P; McLaurin J
    Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14657-62. PubMed ID: 15297619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages.
    Asuni AA; Boutajangout A; Scholtzova H; Knudsen E; Li YS; Quartermain D; Frangione B; Wisniewski T; Sigurdsson EM
    Eur J Neurosci; 2006 Nov; 24(9):2530-42. PubMed ID: 17100841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Developing novel immunogens for an effective, safe Alzheimer's disease vaccine.
    Maier M; Seabrook TJ; Lemere CA
    Neurodegener Dis; 2005; 2(5):267-72. PubMed ID: 16909008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Active immunization with the peptide epitope vaccine Aβ3-10-KLH induces a Th2-polarized anti-Aβ antibody response and decreases amyloid plaques in APP/PS1 transgenic mice.
    Ding L; Meng Y; Zhang HY; Yin WC; Yan Y; Cao YP
    Neurosci Lett; 2016 Nov; 634():1-6. PubMed ID: 27693663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's-like mice.
    Crehan H; Liu B; Kleinschmidt M; Rahfeld JU; Le KX; Caldarone BJ; Frost JL; Hettmann T; Hutter-Paier B; O'Nuallain B; Park MA; DiCarli MF; Lues I; Schilling S; Lemere CA
    Alzheimers Res Ther; 2020 Jan; 12(1):12. PubMed ID: 31931873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
    Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S
    Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice.
    Wang HC; Yu YZ; Liu S; Zhao M; Xu Q
    Vaccine; 2016 Apr; 34(15):1758-66. PubMed ID: 26945100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.
    Panza F; Frisardi V; Imbimbo BP; D'Onofrio G; Pietrarossa G; Seripa D; Pilotto A; Solfrizzi V
    Immunotherapy; 2010 Nov; 2(6):767-82. PubMed ID: 21091109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice.
    Wilcock DM; Colton CA
    CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):50-64. PubMed ID: 19275636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amyloid beta peptide immunotherapy in Alzheimer disease.
    Delrieu J; Ousset PJ; Voisin T; Vellas B
    Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.